Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp; Lorenzo Galluzzi

doi:10.1016/j.trecan.2021.11.006

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp, Lorenzo Galluzzi

Cornell University

Research output: Contribution to journal › Article › peer-review

Abstract

Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Trends in Cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/j.trecan.2021.11.006
State	Published - Jan 2022
Externally published	Yes

Keywords

autophagy
CGAS
immune checkpoint inhibitors
PARP inhibitors
VEGFA
venetoclax
Immunization
Humans
Homologous Recombination
Ovarian Neoplasms/genetics
BRCA1 Protein/genetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2021.11.006

Cite this

@article{7655ef6d886644d4be916a8011c84e17,

title = "Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma",

abstract = "Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.",

keywords = "autophagy, CGAS, immune checkpoint inhibitors, PARP inhibitors, VEGFA, venetoclax, Immunization, Humans, Homologous Recombination, Ovarian Neoplasms/genetics, BRCA1 Protein/genetics",

author = "Vanessa Klapp and Lorenzo Galluzzi",

year = "2022",

month = jan,

doi = "10.1016/j.trecan.2021.11.006",

language = "English",

volume = "8",

pages = "1--3",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

AU - Klapp, Vanessa

AU - Galluzzi, Lorenzo

PY - 2022/1

Y1 - 2022/1

N2 - Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

AB - Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

KW - autophagy

KW - CGAS

KW - immune checkpoint inhibitors

KW - PARP inhibitors

KW - VEGFA

KW - venetoclax

KW - Immunization

KW - Humans

KW - Homologous Recombination

KW - Ovarian Neoplasms/genetics

KW - BRCA1 Protein/genetics

UR - http://www.scopus.com/inward/record.url?scp=85120165119&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2021.11.006

DO - 10.1016/j.trecan.2021.11.006

M3 - Article

C2 - 34840109

AN - SCOPUS:85120165119

SN - 2405-8033

VL - 8

SP - 1

EP - 3

JO - Trends in Cancer

JF - Trends in Cancer

IS - 1

ER -

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this